Aberdeen Group
LGND icon

Aberdeen Group’s Ligand Pharmaceuticals LGND Stock Holding History

Aberdeen Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.5M Buy
172,480
+82,436
+92% +$19.4M 0.08% 214
2026
Q1 		$18M Sell
90,044
-29,265
-25% -$5.79M 0.03% 455
2025
Q4 		$22.6M Sell
119,309
-70,439
-37% -$13.5M 0.03% 393
2025
Q3 		$33.6M Sell
189,748
-39,482
-17% -$5.87M 0.05% 295
2025
Q2 		$26.1M Buy
229,230
+12,989
+6% +$1.39M 0.04% 336
2025
Q1 		$22.7M Buy
216,241
+39,481
+22% +$4.46M 0.04% 361
2024
Q4 		$18.9M Sell
176,760
-72,509
-29% -$8.2M 0.04% 381
2024
Q3 		$24.9M Sell
249,269
-20,874
-8% -$2.1M 0.05% 342
2024
Q2 		$22.8M Sell
270,143
-11,413
-4% -$908K 0.04% 350
2024
Q1 		$20.6M Sell
281,556
-8,862
-3% -$653K 0.04% 400
2023
Q4 		$20.7M Sell
290,418
-29,711
-9% -$1.75M 0.05% 377
2023
Q3 		$19.2M Sell
320,129
-68,671
-18% -$4.52M 0.05% 327
2023
Q2 		$28M Buy
388,800
+107,093
+38% +$8.04M 0.07% 277
2023
Q1 		$20.7M Sell
281,707
-27,272
-9% -$1.94M 0.05% 342
2022
Q4 		$20.6M Sell
308,979
-400,122
-56% -$26M 0.06% 326
2022
Q3 		$38.1M Buy
709,101
+22,079
+3% +$1.3M 0.11% 203
2022
Q2 		$38.2M Buy
687,022
+150,012
+28% +$8.51M 0.12% 180
2022
Q1 		$37.7M Sell
537,010
-44,028
-8% -$3.19M 0.1% 220
2021
Q4 		$56M Buy
581,038
+6,904
+1% +$638K 0.12% 173
2021
Q3 		$49.9M Sell
574,134
-76,325
-12% -$5.9M 0.11% 189
2021
Q2 		$53.2M Buy
650,459
+370,764
+133% +$30.8M 0.12% 172
2021
Q1 		$26.6M Sell
279,695
-311,942
-53% -$29.5M 0.06% 285
2020
Q4 		$36.7M Buy
591,637
+275,859
+87% +$15.7M 0.09% 203
2020
Q3 		$18.8M Buy
+315,778
New +$21.5M 0.05% 309

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group's LGND Position: Q2 2026 in Review

Aberdeen Group increased its Ligand Pharmaceuticals (LGND) stake by 92% in Q2 2026, buying an estimated $19.4M and bringing the position to 172,480 shares worth $54.5M. The position accounts for 0.08% of the portfolio, ranked #214.

Aberdeen Group first reported a position in LGND in Q3 2020 and has held it in 24 quarters since. The position peaked at $56M in Q4 2021. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Aberdeen Group held 172,480 shares of Ligand Pharmaceuticals worth $54.5M as of Q2 2026.
  • Aberdeen Group bought 82,436 Ligand Pharmaceuticals shares in Q2 2026, an estimated $19.4M.
  • Ligand Pharmaceuticals made up 0.08% of Aberdeen Group's portfolio in Q2 2026, its #214 holding.
  • Aberdeen Group first reported a position in Ligand Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • Aberdeen Group's Ligand Pharmaceuticals position peaked at $56M in Q4 2021.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.